Cathepsin's predictive role in breast cancer confirmed
This article was originally published in Clinica
Immunoassay measurements of cathepsin-D can be used to predict the likelihood of relapse among breast cancer patients, researchers in the Netherlands have confirmed. Previous studies based on Western blotting or immunohistochemistry have produced conflicting results about the value of measuring tumour levels of the enzyme.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.